Correlation of high‐risk human papillomavirus genotypes persistence and risk of residual or recurrent cervical disease after surgical treatment

Abstract

The evidence on genotype-specific risk in women infected with human papillomavirus (HPV) with normal cytology and the importance of the distinction of high-risk (HR)-HPV genotypes in the management of low-grade lesions suggest that the distinction of HR-HPV genotypes has the potential to improve the follow-up of patients treated for high-grade cervical lesions. The aims of this study were to define the persistence of the different HR-HPV in the follow-up of surgical treated women, to detect the changes of genotypes from the pre- to the post-operative status, and to evaluate whether genotype-specific persistence can predict the development of residual or recurrent disease during the follow-up. HR-HPV detection and genotyping was carried out by the Linear Array HPV Genotyping Test on cervical cytological samples from 72 women treated by surgery. The 6-month post-operative HPV status was correlated with the pre-operative HPV genotype and with the residual or recurrent disease within 24 months. It was observed that the residual or recurrent disease in women with persistence of HPV 16 and/or HPV 18 was higher (82.4%) than in women with persistence of at least one HR-HPV type of group 2 (HPV 31, 33, 35, 45, 52, and 58) (66.7%) and at least one type of group 3 (HPV 39, 51, 56, 59, 68, 26, 53, 66, 73, and 82) (14.3%). These data defined HR-HPV groups for the risk of progression of disease and suggested that the identification of persistent infection with different HR-HPV genotypes has the potential to improve the management of these patients.

Risk factors for recurrence of vaginal intraepithelial neoplasia in the vaginal vault after laser vaporization

“…However, we found that high-risk HPV infection was more common in patients with VAIN III than those with VAIN I-II, showing linear by linear association like a previous study where positivity to high-risk HPV infection has been reported to be significantly higher in patient with relapse to VAIN after laser vaporization [25]. Moreover, high-risk HPV infection has been shown to increase the rate of recurrence in CIN [26], and to contribute to the development of multifocal lesions known to be a significant risk factor for VAIN [16]. It means that high-risk HPV infection may be associated with advanced-disease of VAIN and it may be a possible risk factor for recurrence in patients treated with laser vaporization due to VAIN.…”

The predictive value of human papillomavirus testing for the outcome of patients conservatively treated for stage IA squamous cell cervical carcinoma

“…Secondly, we can also exclude that positive HPV test results at the initial follow-up visit reflected the transient presence of lowrisk virus types unrelated to the treated lesion [13]. As shown in Table 2, transient post-treatment positive test results were generally caused by the same virus type that infected cancer cells -and not by the presence of different virus types in the cervical/vaginal environment.…”

Modified General Primer PCR System for Sensitive Detection of Multiple Types of Oncogenic Human Papillomavirus

“…HPV genotyping is important for most of the major medical indications of HPV testing. For example, genotyping of HPV has been shown to be an accurate indicator of treatment failure in follow-up after treatment for cervical dysplasia (1,22). In cervical screening, HPV genotyping better identifies women at high risk of dysplasia than does a nongenotyping HPV test (6), and monitoring of the types that are associated with the highest risk for cancer is particularly important (3,22).…”

“…For example, genotyping of HPV has been shown to be an accurate indicator of treatment failure in follow-up after treatment for cervical dysplasia (1,22). In cervical screening, HPV genotyping better identifies women at high risk of dysplasia than does a nongenotyping HPV test (6), and monitoring of the types that are associated with the highest risk for cancer is particularly important (3,22). The monitoring of the effect of HPV vaccination requires adequate HPV genotyping to evaluate whether vaccine HPV types disappear from the population and how the prevalence of nonvaccine types is affected (8).…”